Gut Dysbiosis Reversal Supercharges Anabolic Signaling: How Targeted Nutrition and Resistance Training Rescue Muscle Growth in Aging

A synergistic intervention combining moderate-intensity resistance training with a targeted nutritional stack containing leucine, vitamin D, and specific probiotic strains profoundly upregulated anabolic mTOR and IGF-1 signaling in aged male rats. The combination protocol simultaneously eradicated the pro-inflammatory gut pathobiont Fusobacterium nucleatum, restoring the gut microbiome ratio to youthful baseline levels. This research provides preliminary in vivo evidence linking targeted microbiome modulation directly to the reversal of age-related anabolic resistance, offering a novel gut-muscle axis pathway for treating sarcopenia.

Sarcopenia presents a significant hurdle for longevity, characterized by the progressive loss of skeletal muscle mass and functional strength. A fundamental paradox in aging physiology is that the mechanistic target of rapamycin complex 1 (mTORC1) often becomes hyperactive as organisms age, yet this activation fails to translate into effective muscle protein synthesis. This phenomenon is known as anabolic resistance. Research into the gut-muscle axis strongly suggests that intestinal dysbiosis contributes to this systemic failure. Specifically, age-related shifts in gut bacteria increase intestinal permeability and systemic inflammation, which biochemically blocks muscle growth pathways.

This study sought to break that inflammatory blockade. Researchers subjected aged male Wistar rats, equivalent to 60 to 70 human years, to an eight-week protocol of moderate-intensity ladder climbing. Crucially, they paired this physical stimulus with a precise nutritional intervention delivered after exercise. The stack included Lactobacillus plantarum, Bifidobacterium bifidum, vitamin D, and the amino acid leucine.

The results demonstrated a powerful synergistic effect. Administering either the resistance training or the nutritional supplement alone yielded only modest improvements in anabolic signaling markers. However, the combined intervention radically transformed the biochemical environment. The combination group experienced massive increases in the protein content and gene expression of IGF-1, mTORC1, and S6K1, rivaling the levels seen in young, healthy control rats.

The mechanism behind this restoration appears rooted in the gut microbiome. The combination therapy effectively suppressed Fusobacterium nucleatum, an inflammatory pathobiont known to produce lipopolysaccharides that trigger systemic inflammation. This inflammation normally degrades insulin receptor substrate 1, crippling downstream anabolic signaling. By clearing this bacterial burden and reducing the Firmicutes to Bacteroidetes ratio, the combined intervention removed the inflammatory brake on the mTORC1 pathway. This allowed the mechanical stress of exercise and the nutritional trigger of leucine to effectively stimulate muscle growth pathways.

Actionable Insights

For individuals looking to maximize healthspan and counteract sarcopenia, this paper indicates that resistance training alone may be insufficient if underlying gut dysbiosis and inflammation are present. To overcome age-related anabolic resistance, the data supports consuming a synergistic stack of leucine, vitamin D, Lactobacillus plantarum, and Bifidobacterium bifidum within two hours of completing resistance training.

The effect size of this specific combination is massive compared to exercise alone. In the study, the combination group saw an approximate 375 percent increase in mTORC1 protein content over the aged control baseline, whereas exercise alone yielded a much smaller fractional improvement. Furthermore, the inflammatory gut bacteria Fusobacterium nucleatum was reduced by roughly 3 log units, translating to a 99.9 percent absolute reduction in bacterial DNA replication. This combination of targeted probiotics, a key amino acid, and vitamin D alongside mechanical overload appears necessary to fully unlock the body’s muscle-building potential in older age.

Context/Source

1 Like

For wanting to reproduce the ingredients of this paper, it is easy to find the two listed probiotics, but pretty much impossible to find the specific strains of each used in the study. That may make a difference…no?

I have the paper and had Claude review it to identify the specific strains. Following is that information, but they are research strains, so probably not that much value to you. I guess I would try the closest available consumer-oriented probiotics of the same family.

From Claude:

Strains Used in This Study

Looking at Section 2.6 (Supplement Composition), the paper specifies:

Organism Strain designation Source
Lactobacillus plantarum (LP) PTCC 1058 Persian Type Culture Collection (IROST, Iran)
Bifidobacterium bifidum (Bb) Not given in this paper — just “Bb” —

The paper itself doesn’t give a catalog number for B. bifidum. However, it cites the group’s own earlier protocol paper (Mohabbat & Arazi, Scientific Reports 2024) as the source of the supplement formulation, and that paper specifies both strains explicitly:

  • Lactobacillus plantarum PTCC 1058
  • Bifidobacterium bifidum PTCC 1644

Both obtained from IROST (Iranian Research Organization for Science and Technology), which curates the PTCC.

Cross-referencing PTCC 1058 against the PTCC’s own database, it is equivalent to a very well-known type/reference strain:

  • PTCC 1058 = ATCC 8014 = DSM 20205 (also NCIB 6376, ICPB 2080, NCDO 82) — originally deposited as Lactobacillus arabinosus strain 17-5.

I could not find a published international equivalent (ATCC/DSM/JCM) for PTCC 1644; it appears to circulate mainly as an IROST/PTCC-numbered isolate in Iranian literature.

Important caveat on “commercial sources”

Both of these are laboratory reference/type strains, not proprietary branded probiotic strains (unlike things like L. plantarum 299v or B. bifidum Rosell-71/MIMBb75 that you’d find in retail supplements). I could not find any consumer probiotic supplement that markets itself as containing “PTCC 1058” or “PTCC 1644” specifically — these designations are lab catalog numbers, not marketing strain names.

What is commercially available is the live culture itself, sold to labs for research/QC use (not as a swallowable supplement):

1 Like

Thanks RapAdmin,looking into it